High asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine levels in migraine patients

Basit Öğe Kaydı
dc.authoridGunduz, Ozgur/0000-0002-2470-3021
dc.authoridKaradag, Cetin Hakan/0000-0002-4763-986X
dc.authorwosidGÜNDÜZ, Özgür/AAH-8717-2019
dc.authorwosidGunduz, Ozgur/A-2351-2016
dc.authorwosidKaradag, Cetin Hakan/H-4899-2013
dc.contributor.authorReyhani, Aylin
dc.contributor.authorCelik, Yahya
dc.contributor.authorKaradag, Hakan
dc.contributor.authorGunduz, Ozgur
dc.contributor.authorAsil, Talip
dc.contributor.authorSut, Necdet
dc.date.accessioned2024-06-12T11:08:33Z
dc.date.available2024-06-12T11:08:33Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractExperimental and clinical data strongly suggests that nitric oxide (NO) plays a pivotal role in migraine. This is also supported by studies of migraine induced by substances that release NO. NO is synthesized from L-arginine by endothelial NO synthase (NOS). Asymmetric dimethylarginine (ADMA) is the major endogenous competitive inhibitor of NOS. Symmetric dimethylarginine (SDMA) is an inactive stereoisomer of ADMA. It may reduce NO production by competing with arginine for cellular uptake. The aim of this study was to measure the levels of ADMA, SDMA and L-arginine in migraine patients during the interictal period. One hundred migraine patients and 100 healthy volunteers were recruited. The patients were in the interictal period and classified into two groups as having migraine with aura and migraine without aura. Their serum ADMA, SDMA and L-arginine levels were measured by high-performance liquid chromotography (HPLC) method. ADMA, SDMA and L-arginine levels were significantly higher in migraine patients compared to the control group. But there was no difference between the patients with and without aura. These results suggest that NOS inhibitors and L-arginine/NO pathway plays an important role in migraine pathopysiology.en_US
dc.identifier.doi10.1007/s10072-017-2970-1
dc.identifier.endpage1291en_US
dc.identifier.issn1590-1874
dc.identifier.issn1590-3478
dc.identifier.issue7en_US
dc.identifier.pmid28455769en_US
dc.identifier.scopus2-s2.0-85018318299en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1287en_US
dc.identifier.urihttps://doi.org/10.1007/s10072-017-2970-1
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22478
dc.identifier.volume38en_US
dc.identifier.wosWOS:000404610500016en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofNeurological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMigraineen_US
dc.subjectAsymmetric Dimethylarginineen_US
dc.subjectNitric Oxideen_US
dc.subjectL-Arginineen_US
dc.subjectSymmetric Dimethylarginineen_US
dc.subjectCortical Spreading Depressionen_US
dc.subjectNitric-Oxide Synthaseen_US
dc.subjectEndothelial Dysfunctionen_US
dc.subjectRisk-Factoren_US
dc.subjectStrokeen_US
dc.subjectPrevalenceen_US
dc.subjectInhibitoren_US
dc.titleHigh asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine levels in migraine patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu